Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aquestive TherapeuticsAQST -1.15%49 3-Year EBITDA Growth Rate is 8.60% as of Jun. 2026, which is 65% below its 10-year median of 24.40. GuruFocus rates AQST with a GF Score™ of 49/100 and a GF Value™ of $2.37 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 804 Drug Manufacturers companies, Aquestive Therapeutics ranks worse than 50.75% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 8.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aquestive Therapeutics was 36.30% per year. The lowest was 8.60% per year. And the median was 24.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aquestive Therapeutics 3-Year EBITDA Growth Rate Related Terms
AQST vs TLRY, EOLS, IRWD: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 8.60% mean?
Aquestive Therapeutics (AQST) has a 3-Year EBITDA Growth Rate of 8.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aquestive Therapeutics and its competitors. This is 65% below median its historical median of 24.40. Over the past decade, Aquestive Therapeutics' 3-Year EBITDA Growth Rate has ranged from 8.60 to 36.30. According to the industry distribution chart, Aquestive Therapeutics ranks #408 out of 804 companies in the Drug Manufacturers industry, placing it in the top 50.7%.
Is Aquestive Therapeutics' 3-Year EBITDA Growth Rate too high?
Aquestive Therapeutics' current 3-Year EBITDA Growth Rate of 8.60% is 65% below median its 10-year median of 24.40. Over the past 10 years, this metric has ranged from a low of 8.60 to a high of 36.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Aquestive Therapeutics' value of 8.60% is 3.4% below this industry median. Based on the distribution chart, Aquestive Therapeutics ranks #408 out of 804 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aquestive Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aquestive Therapeutics' 3-Year EBITDA Growth Rate compare to TLRY and EOLS?
According to the Drug Manufacturers industry distribution chart, Aquestive Therapeutics ranks #408 out of 804 companies for 3-Year EBITDA Growth Rate. This places Aquestive Therapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Aquestive Therapeutics' value of 8.60% is 3.4% below this benchmark. Historically, Aquestive Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 8.60 to 36.30 over the past decade. While the company's 10-year median is 24.40 vs. the industry median of 8.90, Aquestive Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aquestive Therapeutics's current 3-Year EBITDA Growth Rate of 8.60% is 3.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aquestive Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aquestive Therapeutics's current 3-Year EBITDA Growth Rate is 8.60%, which is 65% below median its own 10-year median of 24.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquestive Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aquestive Therapeutics (AQST) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.37, compared to a current price of $5.16 — trading 117.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 8.60%, which is 65% below median its 10-year median of 24.40 and 3.4% below the Drug Manufacturers industry median of 8.90. Aquestive Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aquestive Therapeutics (AQST), the current 3-Year EBITDA Growth Rate is 8.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aquestive Therapeutics (AQST) Overvalued in 2026?
Based on GuruFocus' analysis, Aquestive Therapeutics stock appears to be overvalued.
The current stock price of $5.16 is trading 117.7% above its estimated GF Value™ of $2.37.
GuruFocus considers Aquestive Therapeutics to be Significantly Overvalued.
Key valuation signals for AQST:
3-Year EBITDA Growth Rate: 8.60% (65% below median its 10-year median of 24.40)
GF Value™: $2.37 vs. price of $5.16 (117.7% above fair value)
Industry Position: 3.4% below the Drug Manufacturers median (#408 of 804)
No single metric tells the full story. See the AQST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
49GF Score
Get the complete analysis for AQST
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQST has been successfully added to your 
